|
시장보고서
상품코드
2087764
바이탈 사인 모니터링 기기 시장 : 제품 유형, 기술, 용도, 최종 사용자, 판매 채널별 - 세계 시장 예측(2026-2032년)Vital Signs Monitoring Device Market by Product Type, Technology, Application, End User, Sales Channel - Global Forecast 2026-2032 |
||||||
360iResearch
바이탈 사인 모니터링 기기 시장은 2032년까지 연평균 복합 성장률(CAGR) 6.62%로 성장해 99억 8,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 63억 7,000만 달러 |
| 추정 연도(2026년) | 67억 9,000만 달러 |
| 예측 연도(2032년) | 99억 8,000만 달러 |
| CAGR(%) | 6.62% |
생체 징후 모니터링 장비는 단순한 측정 도구에서 벗어나, 병원, 외래 진료, 응급 의료, 재택 간호, 장기 요양 등 각 현장에서 혈압, 맥박수, 호흡수, 체온, 산소 포화도 및 관련 생리학적 지표를 추적하는 네트워크화된 임상 인텔리전스 시스템으로 점차 전환되고 있습니다.
바이탈 사인 모니터링 기기 시장 환경은 일회성 측정 방식에서 지속적이고 무선 방식의 웨어러블 바이탈 사인 모니터링으로의 전환에 따라 재편되고 있습니다. 병원에서는 수기 기록의 감축, 임상 상황의 가시성 향상, 그리고 신속한 치료 단계 상향 조정을 지원하기 위해, 네트워크 연결형 병상 모니터, 휴대용 다중 매개변수 모니터, 간호사 호출/EHR 통합 시스템을 우선적으로 도입하고 있습니다.
인공지능(AI)은 신호 품질 향상, 오경보 감소, 여러 바이탈 사인에 걸친 패턴 감지, 상태 악화 및 패혈증 모니터링, 호흡 부전, 심혈관 사건에 대한 예측적 위험 계층화 지원을 통해 부가가치를 창출하고 있습니다. AI를 활용한 모니터링은 대표적인 데이터셋을 통해 검증되었으며, 명확한 임상 거버넌스 하에 도입된다면 임상의가 환자의 우선순위를 정하는 데 도움이 될 것입니다.
아시아태평양에서는 중국, 인도, 일본, 한국, 호주가 고령화 및 만성 질환을 앓고 있는 대규모 인구층을 대상으로 병원의 디지털화, 현지 의료기기 제조, 원격의료 인프라 및 원격 돌봄 모델에 대한 투자를 추진하고 있어 시장이 확대되고 있습니다. 북미에서는 선진적인 병원 인프라, 원격 환자 모니터링에 대한 보험 급여 제도, FDA 승인을 받은 커넥티드 기기, 가치 기반 의료(VBC) 추진, 그리고 재택 간호에 대한 높은 수요 덕분에 도입이 계속해서 적극적으로 진행되고 있습니다.
아세안 시장에서는 공립 병원, 민간 의료 네트워크, 지역 보건 프로그램 및 모바일 헬스 이니셔티브를 위한 확장성이 뛰어난 모니터링 솔루션이 우선시되고 있으며, 디지털 헬스 정책, 의료 관광, 그리고 확대되는 중산층의 접근성이 교차하는 지역에서 수요가 가장 높습니다. GCC 국가들에서는 스마트 병원, 국가 보건 개혁 프로그램, 중증 환자 대상 전문 의료에 대한 투자, 그리고 디지털화된 공중보건 시스템을 통해 최첨단 연결형 모니터링 시스템이 도입되고 있습니다.
미국은 원격 환자 모니터링, 재택 병원 도입, FDA 승인을 받은 커넥티드 기기, 그리고 가치 기반 진료 모델 분야에서 선도적인 위치를 차지하고 있으며, 만성 질환의 유병률이 지속적인 임상 수요를 뒷받침하고 있습니다. 캐나다는 주 차원의 디지털 헬스 통합, 농촌 지역 접근성 확보, 그리고 공정한 모니터링 체계 구축을 중시하는 반면, 멕시코와 브라질은 사립 병원, 원격의료 도입, 그리고 공중보건 인프라 현대화를 통해 진전을 보이고 있습니다.
업계 선도 기업들은 임상적으로 검증된 정확도, 전자건강기록(EHR) 및 병원 정보 시스템과의 상호 운용성, 신뢰할 수 있는 경보 관리, 그리고 ‘사이버 보안 바이 디자인’을 우선시해야 합니다. 지속적인 모니터링, 원격 환자 모니터링, 다중 매개변수 워크플로우 및 안전한 데이터 교환을 지원하는 기기는 의료 서비스가 병원 밖으로 확대됨에 따라 더욱 유리한 입지를 차지하게 될 것입니다.
본 조사 방법은 공중보건 기관, 규제 당국, 임상 지침, 보험 급여 정책, 병원의 조달 패턴, 동료 심사를 거친 문헌 및 의료 기술 관련 자료에 대한 2차 조사와, 업계 관계자, 임상의, 조달 전문가, 의료 이해관계자에 의한 1차 검증을 결합한 것입니다.
의료 시스템이 고령화 사회, 만성 질환의 부담, 인력 부족, 재택 간호에 대한 수요 증가에 대응해 나가는 가운데, 바이탈 사인 모니터링 기기는 커넥티드 케어의 기반이 되어가고 있습니다. 가장 큰 비즈니스 기회는 임상 수준의 정확도, 원활한 연결성, 효율적인 워크플로우, 입증된 성능, 그리고 안전한 데이터 교환을 모두 갖춘 기기에서 비롯될 것입니다.
The Vital Signs Monitoring Device Market is projected to grow by USD 9.98 billion at a CAGR of 6.62% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 6.37 billion |
| Estimated Year [2026] | USD 6.79 billion |
| Forecast Year [2032] | USD 9.98 billion |
| CAGR (%) | 6.62% |
Vital signs monitoring devices are moving from episodic measurement tools to connected clinical intelligence systems that track blood pressure, pulse rate, respiratory rate, temperature, oxygen saturation, and related physiological parameters across hospitals, ambulatory care, emergency medicine, home care, and long-term care settings.
Demand is supported by verified public health fundamentals: the World Health Organization links noncommunicable diseases to most global deaths, while United Nations population data confirms rapid aging across every major region. These trends increase the need for continuous patient monitoring, remote patient monitoring, early deterioration detection, and workflow-efficient vital signs monitoring devices that support timely clinical intervention.
The vital signs monitoring device landscape is being reshaped by the shift from spot-check measurement to continuous, wireless, and wearable vital signs monitoring. Hospitals are prioritizing connected bedside monitors, portable multiparameter monitors, and nurse-call/EHR-integrated systems to reduce manual documentation, improve clinical visibility, and support faster escalation of care.
Outside acute care, hospital-at-home programs, chronic disease management, virtual wards, and telehealth reimbursement are accelerating adoption of remote patient monitoring devices. Buyers increasingly evaluate interoperability, battery life, sensor accuracy, alarm performance, cybersecurity, cloud connectivity, usability, and regulatory compliance alongside price, making evidence-based performance and integration capability central to competitive positioning.
Artificial intelligence is adding value by improving signal quality, reducing false alarms, detecting patterns across multiple vital signs, and supporting predictive risk stratification for deterioration, sepsis surveillance, respiratory compromise, and cardiac events. AI-enabled monitoring can help clinicians prioritize patients when validated with representative datasets and deployed with clear clinical governance.
Regulators are also shaping adoption. The U.S. FDA treats many AI-enabled monitoring functions as software as a medical device, while the European framework combines MDR requirements, GDPR privacy obligations, and the EU AI Act. Industry leaders must prove safety, explainability, bias control, cybersecurity, human oversight, and post-market performance before scaling AI-enabled vital signs monitoring.
Asia-Pacific is advancing as China, India, Japan, South Korea, and Australia invest in hospital digitization, local device manufacturing, telehealth infrastructure, and remote care models for large aging and chronic disease populations. North America remains highly adoption-oriented due to advanced hospital infrastructure, remote patient monitoring reimbursement pathways, FDA-cleared connected devices, value-based care initiatives, and strong demand for home-based care.
Latin America is gaining momentum through Brazil and Mexico, where private hospital networks, telehealth expansion, and public-sector modernization support adoption of vital signs monitoring devices. Europe emphasizes MDR compliance, GDPR-aligned data protection, procurement quality, clinical evidence, and interoperability, while the Middle East is driven by GCC smart-hospital programs, national health transformation strategies, and healthcare infrastructure investment. Africa's opportunity is concentrated in affordable, rugged, mobile-enabled vital signs monitoring for primary care, maternal health, infectious disease programs, emergency response, and expanding urban hospitals.
ASEAN markets are prioritizing scalable monitoring solutions for public hospitals, private care networks, community health programs, and mobile health initiatives, with demand strongest where digital health policy, medical tourism, and expanding middle-class access intersect. GCC countries are adopting premium connected monitoring through smart hospitals, national health transformation programs, high-acuity specialty care investments, and digitally enabled public health systems.
The European Union favors CE-marked, interoperable, privacy-compliant devices that meet MDR expectations, GDPR obligations, and cross-border procurement standards. BRICS countries combine large patient populations with growing local manufacturing, public hospital expansion, and cost-sensitive procurement, while G7 markets lead in advanced monitoring, reimbursement maturity, clinical validation, and integration with digital care pathways. NATO-aligned health systems increasingly consider supply-chain resilience, cybersecurity, emergency preparedness, and standardized medical technology procurement as strategic priorities.
The United States leads in remote patient monitoring, hospital-at-home adoption, FDA-cleared connected devices, and value-based care models, with chronic disease prevalence supporting sustained clinical demand. Canada emphasizes provincial digital health integration, rural access, and equitable monitoring pathways, while Mexico and Brazil show progress through private hospitals, telemedicine adoption, and modernization of public health infrastructure.
In Europe, the United Kingdom is scaling virtual wards and NHS remote monitoring pathways; Germany benefits from strong medical device manufacturing, hospital digitization, and digital health reimbursement; France, Italy, and Spain are advancing hospital modernization, home care, and aging-care monitoring; and Russia's market is shaped by domestic procurement, localization policies, and hospital infrastructure needs.
China is expanding through large hospital networks, domestic medtech capacity, public health digitization, and elderly-care demand. India's opportunity is driven by affordability, high patient volumes, telehealth, government-supported local manufacturing, and expanding private healthcare. Japan prioritizes elderly care, hospital efficiency, and precision monitoring, Australia supports remote care for dispersed populations, and South Korea combines connected hospitals, strong electronics capability, broadband infrastructure, and digital health adoption.
Industry leaders should prioritize clinically validated accuracy, interoperability with EHR and hospital information systems, reliable alarm management, and cybersecurity-by-design. Devices that support continuous monitoring, remote patient monitoring, multiparameter workflows, and secure data exchange will be better positioned as care shifts beyond the hospital.
Manufacturers should develop region-specific portfolios: premium AI-enabled monitors for mature systems, cost-effective portable devices for emerging markets, and rugged mobile solutions for community care. Strategic partnerships with hospitals, telehealth providers, cloud platforms, distributors, and payers can accelerate adoption, while post-market evidence, usability testing, regulatory readiness, and lifecycle software support should remain core to product strategy.
The research methodology combines secondary research from public health agencies, regulatory bodies, clinical guidelines, reimbursement policies, hospital procurement patterns, peer-reviewed literature, and healthcare technology documentation with primary validation from industry participants, clinicians, procurement specialists, and healthcare stakeholders.
The analysis emphasizes verified sources, consistency checks, regulatory review, market segmentation logic, qualitative validation, and triangulation of publicly available evidence to produce decision-ready insights for manufacturers, investors, providers, distributors, and digital health partners. The methodology avoids unsupported assumptions and focuses on evidence-based demand drivers, adoption barriers, technology trends, and regional healthcare priorities.
Vital signs monitoring devices are becoming foundational to connected care as health systems manage aging populations, chronic disease burdens, staffing constraints, and rising demand for care at home. The strongest opportunities will come from devices that combine clinical-grade accuracy, seamless connectivity, workflow efficiency, validated performance, and secure data exchange.
Artificial intelligence, remote patient monitoring, wearable sensors, and interoperable platforms will continue to shape competition, but adoption will depend on validation, trust, usability, data protection, and regulatory compliance. Companies that align product design with regional care models, procurement expectations, and evidence-based clinical priorities are best positioned for sustainable growth.